UNCY
Unicycive Therapeutics Inc

2,988
Loading...
Loading...
News
all
press releases
Buy Rating Maintained for Unicycive Therapeutics Amidst OLC NDA Submission and Strong Financial Outlook
Maxim Group analyst Jason McCarthy has maintained their bullish stance on UNCY stock, giving a Buy rating on September 3. Jason McCarthy has given...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Buy Rating Affirmed for Unicycive Therapeutics Amid Positive Clinical Feedback and Strong Market Entry Potential
Maxim Group analyst Jason McCarthy has reiterated their bullish stance on UNCY stock, giving a Buy rating today. Jason McCarthy has given his Buy r...
TipRanks Financial Blog·1y ago
News Placeholder
Buy Rating for Unicycive Therapeutics Backed by Strong OLC Patient Preference and Positive Revenue Projections
Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Unicycive Therapeutics (UNCY Research Report). The associated price target...
TipRanks Financial Blog·1y ago
News Placeholder
Unicycive Therapeutics initiated with bullish view at Piper Sandler, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
HC Wainwright Reaffirms Buy Rating for Unicycive Therapeutics (NASDAQ:UNCY)
HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a report published on Monday, Benzinga reports. The firm currently has a $4.50 price...
Ticker Report·1y ago
News Placeholder
Buy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial Footing
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY Research Report), with a price t...
TipRanks Financial Blog·2y ago
News Placeholder
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 62.0%
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 56,700 shares, a...
Ticker Report·2y ago
News Placeholder
UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·2y ago
News Placeholder
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury UNI-494 Phase 1 Single Ascending Dose...
Globe Newswire·2y ago
News Placeholder
Unicycive Therapeutics reports FY23 EPS ($1.28), consensus ($1.24)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest UNCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.